目的 探討正心泰顆粒聯(lián)合美托洛爾治療不穩(wěn)定型心絞痛的臨床療效。方法 選取2019年1月—2020年1月在阜外華中心血管病醫(yī)院心血管外科住院的80例不穩(wěn)定型心絞痛患者，隨機分為對照組和治療組，每組各40例。對照組口服酒石酸美托洛爾片，1片/次，2次/d。治療組患者在對照組的基礎上口服正心泰顆粒，1袋/次，3次/d。兩組均連續(xù)治療14 d。觀察兩組患者的臨床療效，同時比較兩組患者治療前后心率、心絞痛每日發(fā)作頻率、發(fā)作持續(xù)時間指標、肌酸激酶同工酶（CK-MB）、乳酸脫氫酶（LDH）、肌酸激酶（CK）、心肌肌鈣蛋白（cTnI）水平，比較兩組患者治療前后白細胞介素6（IL-6）、腫瘤壞死因子（TNF-α）、血同型半胱氨酸（HCY）、超敏C反應蛋白（hs-CRP）水平。結果 治療后，治療組總有效率是95.00%，顯著高于對照組的72.50%（P<0.05）。治療后，兩組患者心率、心絞痛每日發(fā)作頻率、發(fā)作持續(xù)時間均顯著低于同組治療前（P<0.05）；治療后，治療組這些臨床癥狀發(fā)作情況優(yōu)于對照組（P<0.05）。治療后，兩組患者CK-MB、LDH、CK、cTnI均較治療前顯著降低（P<0.05）；治療后，治療組心肌酶水平顯著低于對照組（P<0.05）。治療后，兩組患者IL-6、TNF-α、HCY、hs-CRP水平均顯著降低（P<0.05）；治療后，治療組血清炎性因子水平低于對照組（P<0.05）。結論 正心泰顆粒聯(lián)合美托洛爾治療不穩(wěn)定型心絞痛患者臨床療效顯著提升，并能改善心肌缺血狀態(tài)，降低炎性因子水平，在臨床上值得借鑒與推廣使用。

Objective To investigate the efficacy of Zhengxintai Granules combined with metoprolol in treatment of unstable angina pectoris. Methods A total of 80 patients with unstable angina pectoris who were hospitalized in the Department of Cardiovascular Surgery of Fuwai Central China Cardiovascular Hospital from January 2019 to January 2020 were randomly divided into control group and treatment group, with 40 patients in each group. Patients in the control group were po administered with Metoprolol Tartrate Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Zhengxintai Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and heart rate, daily frequency of attack, duration of angina, creatine kinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), creatine kinase (CK), and myocardial troponin (cTnI) levels in two groups before and after treatment were compared. The levels of interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), blood homocysteine (HCY), hypersensitive C-reactive protein (hs CRP) in two groups were compared. Results After treatment, the total effective rate of treatment group was 95.00%, which was significantly higher than that of control group (72.50%, P<0.05). After treatment, heart rate, daily attack frequency and duration of angina pectoris in two groups were significantly lower than before treatment (P<0.05). After treatment, the onset of these clinical symptoms in the treatment group was better than that in the control group (P<0.05). After treatment, the levels of CK-MB, LDH, CK, and cTnI in two groups were significantly decreased compared with before treatment (P<0.05). After treatment, the level of myocardial enzyme in treatment group was significantly lower than that in control group (P<0.05). After treatment, the levels of IL-6, TNF-α, Hcy, and hs-CRP in two groups were significantly decreased (P<0.05). After treatment, the level of serum inflammatory factors in treatment group was lower than that in control group (P<0.05). Conclusion Zhengxintai Granules combined with metoprolol has significantly improved clinical efficacy in treatment of unstable angina pectoris, and can improve myocardial ischemia, and can reduce the level of inflammatory factors, which is worthy of reference and promotion in clinical use.

R972